Pathways analyses of schizophrenia GWAS focusing on known and novel drug targets

  • Published 2017

Abstract

Using successful genome-wide association results in psychiatry for drug repurposing is an ongoing challenge. Databases collecting drug targets and gene annotations are growing and can be harnessed to shed a new light on psychiatric disorders. We used GWAS summary statistics from the Psychiatric Genetics Consortium (PGC) Schizophrenia working group and a repositioning model for schizophrenia by testing the enrichment of antipsychotics. As sample size increases, schizophrenia GWAS results show increasing enrichment for known antipsychotic drugs, selective calcium channel blockers, and antiepileptics. Each of these therapeutical classes targets different gene subnetworks. We identify 162 Bonferroni-significant druggable genes, and 128 FDR-significant biological pathways related to neurons, synapses, genic intolerance, membrane transport, epilepsy, and mental disorders. These results suggest that, in schizophrenia, current well-powered GWAS results can reliably detect known schizophrenia drugs and thus may hold considerable potential for the identification of new therapeutic leads. Moreover, antiepileptics and calcium channel blockers may provide repurposing opportunities. This study also reveals significant pathways in schizophrenia that were not identified previously, and provides a workflow for pathway analysis and drug repurposing​ ​using​ ​GWAS ​ ​results. 2 peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/091264 doi: bioRxiv preprint first posted online Dec. 2, 2016;

4 Figures and Tables

Cite this paper

@inproceedings{2017PathwaysAO, title={Pathways analyses of schizophrenia GWAS focusing on known and novel drug targets}, author={}, year={2017} }